logo

Matinas Biopharma Holdings, Inc. (MTNB)



Trade MTNB now with
  Date
  Headline
2/1/2021 6:31:45 AM Matinas:Primary Endpoint Of Percent Change From Baseline To End Of Treatment In TG Did Not Meet Statistical Significance
12/1/2020 7:17:08 AM Matinas BioPharma Appoints Hui Liu As Chief Technology Officer
9/15/2020 7:30:55 AM Matinas BioPharma Announces Positive End Of Phase 2 Meeting With FDA For MAT9001 In Severe Hypertriglyceridemia
9/14/2020 7:10:45 AM Matinas BioPharma Appoints Natasha Giordano To Board
10/14/2019 7:06:32 AM Matinas BioPharma Initiates EnACT Study Of MAT2203 For Fungal Cryptococcal Meningitis
9/25/2019 7:10:22 AM Matinas Begins Pre-screening Patients To Determine Eligibility For ENHANCE-IT
1/3/2019 8:21:53 AM Matinas BioPharma Names Keith Kucinski CFO
12/19/2018 8:38:41 AM Matinas BioPharma Names Harold Bays To Its Cardiovascular Health Scientific Advisory Board
11/12/2018 7:04:56 AM Matinas BioPharma 9-month Loss Per Share $0.12 Vs Loss $0.32 Last Year
8/10/2018 8:16:46 AM Matinas BioPharma Q2 Loss Per Share $0.4, Same As Last Year
6/22/2018 8:31:35 AM Matinas BioPharma Announces Closing Of $8.0 Mln Public Offering
6/19/2018 8:06:46 AM Matinas BioPharma Announces Pricing Of $8.0 Mln Public Offering
5/10/2018 7:25:05 AM Matinas BioPharma Q1 Loss Per Share $0.05 Vs Loss $0.25 Last Year
1/8/2018 7:06:08 AM Matinas BioPharma Reports Statistical Endpoint For Success In Phase 2a Clinical Study Of Orally-Administered MAT2203